What is the recommended antimicrobial regimen, duration, and monitoring for treating neurobrucellosis?

Neurobrucellosis Treatment

For neurobrucellosis, use a triple-drug regimen of doxycycline 100 mg twice daily plus rifampicin 600-900 mg once daily plus ceftriaxone 2 g IV daily, continued for a minimum of 3-6 months with individualized extension based on clinical and CSF response.

Recommended Antimicrobial Regimen

First-Line Triple Therapy

• Doxycycline 100 mg orally twice daily for the entire treatment duration provides intracellular penetration essential for Brucella eradication 1
• Rifampicin 600-900 mg orally once daily for the entire treatment duration enhances CNS penetration and acts synergistically with doxycycline 1, 2
• Ceftriaxone 2 g IV daily should be added as the third agent due to its high CSF concentration and demonstrated efficacy in neurobrucellosis 3, 1

Rationale for Ceftriaxone

• Ceftriaxone achieves significantly higher CSF concentrations than other beta-lactams, offering theoretical and clinical advantages in CNS infections 1
• In a case series of 11 neurobrucellosis patients treated with ceftriaxone-based regimens, no deaths occurred and most patients achieved favorable outcomes 3
• Ceftriaxone should be used as the initial parenteral component, particularly in acute presentations 3, 1

Alternative When Ceftriaxone Unavailable

• If ceftriaxone cannot be used, substitute with gentamicin 5 mg/kg IV once daily for the first 7-14 days combined with doxycycline and rifampicin 4
• Gentamicin is preferred over streptomycin because streptomycin has questionable CSF penetration and potential neurotoxicity that may confound neurological assessment 1

Treatment Duration

Minimum Duration

• A minimum of 6 months of combination therapy is required for neurobrucellosis, substantially longer than the 6 weeks used for uncomplicated brucellosis 3, 1
• Some experts recommend 3-6 months, but the weight of evidence supports at least 6 months to prevent relapse 4, 3

Duration Individualization

• Extend treatment beyond 6 months if CSF abnormalities persist, neurological deficits fail to improve, or imaging shows ongoing inflammation 3, 1
• Parenteral ceftriaxone can typically be transitioned to oral therapy after 2-4 weeks once clinical stabilization occurs, while continuing doxycycline and rifampicin for the full duration 3

Monitoring Strategy

Baseline Assessment

• Obtain MRI of brain and spine at diagnosis, as MRI is superior to CT for detecting parenchymal lesions, abscesses, and spinal involvement 5, 4
• Perform lumbar puncture to document CSF pleocytosis (typically <419 × 10⁶/L), elevated protein, and hypoglycorrhachia 6
• Send CSF culture and Brucella serology (CSF agglutination titers), though CSF cultures are positive in only 25-30% of cases 6
• Check serum Brucella agglutination titers (positive in 100% of neurobrucellosis cases) and blood cultures (positive in ~40% of cases) 6

Serial Monitoring During Treatment

• Repeat lumbar puncture at 2-3 months to assess CSF normalization; persistent pleocytosis or elevated protein warrants treatment extension 1
• Repeat MRI at 3 months and 6 months to document resolution of parenchymal lesions or abscesses 3
• Monitor clinical neurological examination monthly for improvement in focal deficits, cranial neuropathies, or altered mental status 6, 2
• Follow serum Brucella titers every 4-6 weeks; a fourfold decline suggests treatment response, though titers may remain elevated for months 6

End-of-Treatment Assessment

• Perform final lumbar puncture at completion of therapy to confirm CSF normalization before discontinuing antibiotics 1
• Obtain final MRI to document radiographic resolution 3

Special Considerations and Pitfalls

Spinal Involvement (Brucellar Spondylitis)

• Always perform MRI of the entire spine when neurobrucellosis is suspected, regardless of whether back pain is present, as spinal involvement is common and may be asymptomatic initially 5, 4
• Aminoglycoside-containing regimens may be superior to rifampicin-only regimens for spondylodiscitis, supporting the use of ceftriaxone or gentamicin in the initial phase 5, 4
• Immobilize the cervical spine if cervical vertebral involvement is present to prevent catastrophic neurological complications from vertebral collapse 5

Corticosteroid Use

• Corticosteroids have been used in specialized situations such as severe cerebral edema, optic neuritis, or vasculitis, but evidence is limited to case reports 1
• Consider dexamethasone 0.15 mg/kg every 6 hours for 2-4 days in patients with papilledema, increased intracranial pressure, or cranial nerve involvement, then taper rapidly 2

Common Pitfalls to Avoid

• Do not use streptomycin in neurobrucellosis due to poor CSF penetration and risk of ototoxicity that may worsen or mimic disease-related hearing loss 1
• Do not use trimethoprim-sulfamethoxazole (TMP-SMX) as monotherapy or dual therapy; TMP-SMX should only be considered as a third agent in triple regimens, as dual regimens without doxycycline have unacceptably high failure rates 5
• Do not shorten treatment to less than 6 months based solely on clinical improvement, as microbiological cure lags behind symptom resolution and premature discontinuation leads to relapse 3, 1
• Do not rely on imaging alone to guide treatment decisions; CSF parameters are more reliable indicators of treatment response 3

Rifampicin in TB-Endemic Areas

• In regions where tuberculosis and brucellosis coexist, weigh the public health risk of rifampicin monotherapy promoting mycobacterial resistance against the individual patient's need for effective neurobrucellosis treatment 7, 4
• This concern is less relevant in neurobrucellosis because rifampicin is always used in combination with at least two other active agents 1, 2

Expected Outcomes

Prognosis

• With appropriate treatment, most patients achieve full recovery or significant improvement 3, 2
• Permanent neurological sequelae occur in 20-40% of cases, most commonly irreversible hearing loss (4 of 18 patients in one series), followed by visual impairment and motor deficits 6
• Mortality is rare (<5%) with modern combination therapy, but can occur from complications such as mycotic aneurysm rupture or severe meningovascular disease 6

Relapse Risk

• Relapse rates are higher in neurobrucellosis than uncomplicated brucellosis, emphasizing the need for prolonged therapy and close monitoring 1
• Relapses typically occur within 6-12 months of treatment completion and usually respond to retreatment with the same regimen extended for an additional 3-6 months 7